ashwagandhaadaptogensstresscortisolnatural healthAustralia

Ashwagandha Benefits, Dosage, and Research: Evidence Review 2026

Q: Morning or night — when is the best time to take it?

The answer depends on your primary goal. For stress and cortisol management, splitting the dose (morning and evening) mirrors published trial protocols and aligns with the cortisol diurnal curve. For sleep-focused use, a single evening dose 30–60 minutes before bed is the most evidence-aligned approach. For athletic performance, taking it around training sessions is a reasonable approach, though the evidence supports consistent daily use more than acute timing effects.

Q: Which form is best — KSM-66, Sensoril, or powder?

For most applications, KSM-66 is the better-evidenced starting point — it has the largest and most diverse human RCT portfolio, covers stress, cortisol, testosterone, and athletic performance applications, and is available at appropriate doses in multiple Australian products. Sensoril is a credible alternative, particularly for sleep-focused use or where a lower dose is preferred. Non-standardised ashwagandha powder has thousands of years of traditional use but makes it difficult to reliably achieve the doses studied in clinical trials — the withanolide content of bulk powders varies significantly by batch and source.

23 February 2026 · 24 min read

This article is for educational purposes only. Ashwagandha is a supplement, not a medicine. Consult a qualified healthcare practitioner before use, especially if you have a thyroid condition, are pregnant, or take medications.

Ashwagandha benefits have attracted more peer-reviewed clinical attention than any other adaptogen in the past two decades — and the research has largely held up to scrutiny. Whether you have encountered it at an Australian health food store, had it recommended by a naturopath, or simply noticed it appearing consistently in the natural health literature, the underlying science is worth engaging with directly.

This review covers what clinical trials actually show about ashwagandha benefits — stress and cortisol reduction, sleep quality, testosterone support, thyroid modulation, and athletic performance — along with extract standardisation, dosage evidence, and the safety considerations that matter most for Australian consumers. No hype; no dismissal. Just an honest look at what the research shows and where the gaps remain.

What Is Ashwagandha?

Ashwagandha (Withania somnifera) is a small, woody shrub native to India, North Africa, and parts of the Mediterranean. In Ayurvedic medicine — the traditional healing system of the Indian subcontinent — it has been classified for more than 3,000 years as a rasayana: a rejuvenating tonic thought to promote longevity, vitality, and resilience under stress.

The name itself translates roughly from Sanskrit as "smell of horse," a reference both to the root's distinctive odour and to the belief that it conferred horse-like stamina. It is also commonly called Indian ginseng and winter cherry, though it is botanically unrelated to true ginseng (Panax species).

Botanical Family and Nightshade Considerations

Ashwagandha belongs to Solanaceae — the nightshade family, the same botanical family as tomatoes, capsicum, potato, and eggplant. This is clinically relevant: people with documented nightshade sensitivity may react to ashwagandha, and this should be considered before use. The plant produces small, berry-like fruit that are toxic, though they are not part of any commercial preparation.

Root vs Leaf: Why the Source Material Matters

The root is the traditional Ayurvedic preparation and the source used in the majority of high-quality standardised extracts. Root-derived extracts have a withanolide profile dominated by withanolide D, withanolide A, and withanoside IV — the compounds best characterised in human trials.

The leaf contains a higher concentration of withanolides by percentage, including a greater proportion of withaferin A. This is pharmacologically active but has a narrower therapeutic window in some preclinical models. Leaf-derived or combined root-leaf extracts — the basis of Sensoril — achieve higher standardised withanolide content by percentage, but the composition differs meaningfully from root-only extracts.

KSM-66 vs Sensoril: Standardisation Explained

Two branded extract formats dominate the Australian and international market:

KSM-66 (Ixoreal Biomed) is a full-spectrum root-only extract produced without alcohol solvents, using a milk-and-water extraction consistent with traditional Ayurvedic preparation. It is standardised to a minimum of 5% withanolides and carries the largest human clinical trial portfolio of any ashwagandha extract. The majority of well-cited RCTs use KSM-66.

Sensoril (Natreon Inc.) uses both root and leaf, standardised to 10% withanolides or more — a higher percentage, but with a different withanolide composition due to the leaf contribution. Sensoril has a smaller but credible trial base, and is often preferred in sleep-focused formulations where the slightly different bioactive profile appears relevant.

A quality label will state the extract name, withanolide percentage, and the dose per serving. Products that list only "ashwagandha extract" without extract identity or standardisation data are difficult to evaluate clinically.

How Ashwagandha Works: Withanolides and the Adaptogenic Mechanism

The adaptogen category — coined by Soviet pharmacologist Nikolai Lazarev in 1947 — describes substances that increase non-specific resistance to stress without disrupting normal biological function or producing dependence. Ashwagandha is the most comprehensively researched plant in this category, and its mechanisms are now reasonably well characterised.

Withanolides: The Primary Active Class

Withanolides are steroidal lactones unique to Withania somnifera. The most studied include:

Withaferin A — demonstrating anti-inflammatory and anti-tumour activity in preclinical models; the most pharmacologically potent, with the narrowest therapeutic window
Withanolide D — anti-stress and immunomodulatory effects in animal studies
Withanolide A — neuroprotective properties; promotes axon and dendrite outgrowth in hippocampal neurons in preclinical models

Beyond withanolides, ashwagandha contains alkaloids (including isopelletierine and anaferine) and saponins (sitoindosides I–VII), which contribute to its adaptogenic and immune-modulating effects.

HPA Axis Modulation

The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress-response system. When triggered by a stressor — physical, psychological, or metabolic — the hypothalamus releases corticotropin-releasing hormone (CRH), which prompts the pituitary to release adrenocorticotropic hormone (ACTH), which drives the adrenal cortex to produce cortisol.

Withanolides appear to modulate this cascade at multiple points: influencing glucocorticoid receptor sensitivity, supporting DHEA-S levels, and normalising the feedback signalling that prevents cortisol from remaining chronically elevated. This is distinct from pharmacological cortisol suppression — ashwagandha appears to help the system self-regulate rather than directly blocking the pathway.

NF-kB Inhibition and Inflammatory Modulation

Withaferin A and related withanolides are potent inhibitors of NF-kB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) — the master transcription factor governing inflammatory gene expression. NF-kB activation drives production of COX-2, TNF-α, IL-6, and other pro-inflammatory mediators. Ashwagandha's suppression of NF-kB partially explains its anti-inflammatory and recovery-supporting effects, mechanisms that intersect with those explored in turmeric curcumin benefits.

GABA-Mimetic Activity

A distinct and practically important mechanism: withanolides appear to have partial agonist activity at GABA-A receptors. This provides a neurochemical basis for the relatively rapid calming effect that some users report within days to weeks of starting, before the longer-term HPA axis changes emerge. It does not produce sedation at standard doses — the effect is better characterised as a reduction in background neurological noise rather than pharmacological blunting.

Researchers interested in biological response modifiers across botanical and peptide domains can explore adaptogenic peptide research compounds for context on how different classes of molecules interact with stress and recovery pathways. The adaptogenic mechanism of ashwagandha operates through HPA axis normalisation and withanolide-mediated receptor activity — a distinct pathway from peptide-based biological modifiers, but one that shares downstream effects on cortisol and inflammatory signalling.

Stress and Cortisol: What Clinical Trials Show

This is the most robustly evidenced domain of ashwagandha benefits, with multiple independent RCTs demonstrating consistent, reproducible findings.

Chandrasekhar et al. 2012 (IPGT RCT)

The landmark trial in this area was published by Chandrasekhar and colleagues in the Indian Journal of Psychological Medicine (2012). This was a double-blind, randomised, placebo-controlled study conducted at the Institute of Postgraduate Teaching and Research (IPGT) involving 64 adults with a history of chronic stress, randomised to receive either 300 mg KSM-66 root extract twice daily (600 mg total) or placebo for 60 days.

Results:

Serum cortisol reduced by 27.9% in the ashwagandha group vs 7.9% in placebo
Statistically significant improvements on the Perceived Stress Scale (PSS), General Health Questionnaire (GHQ-28), and Depression Anxiety Stress Scale (DASS)
No clinically significant adverse effects reported

This is the most-cited ashwagandha human RCT and remains methodologically sound by the standards applied to the evidence at publication.

Pratte et al. 2014

A separate 8-week double-blind RCT by Pratte and colleagues, published in the Journal of the American Nutraceutical Association, examined 500 mg ashwagandha root extract in adults with elevated stress scores. The ashwagandha group showed significant improvements on the Hamilton Anxiety Scale and validated stress assessment tools compared to placebo. This trial is notable for using a different extract format from KSM-66, providing independent replication of the cortisol and stress findings.

2-Month KSM-66 Trial (240 mg Daily)

A 2019 trial published in Medicine (Baltimore) found that 240 mg daily of a concentrated ashwagandha extract produced meaningful reductions in morning salivary cortisol, perceived stress, and anxiety scores compared to placebo at the 8-week mark. This is clinically useful: it confirms that lower doses of more concentrated extracts can produce comparable effects to the 600 mg/day doses used in the Chandrasekhar study, suggesting the dose-response relationship is not simply linear.

The consistency across these independent trials — different doses, different extract forms, different populations, different countries — is a meaningful signal. The cortisol-reducing effect of ashwagandha at 2 months is among the best-replicated findings in the adaptogen literature.

Ashwagandha for Sleep Quality

One of the less prominent but consistently replicated ashwagandha benefits is its effect on sleep — studied as a primary outcome in its own right, not merely as a secondary consequence of reduced anxiety.

Shoden Extract 120 mg Trial

A particularly notable study used Shoden, a patented ashwagandha extract standardised to a very high withanolide content (35% withanolide glycosides). A 2019 double-blind, placebo-controlled trial published in PLOS ONE enrolled 60 adults reporting insomnia and randomised them to 120 mg Shoden extract or placebo for 10 weeks. This is a much lower withanolide dose than the KSM-66 cortisol trials, but the high standardisation percentage means the absolute withanolide load is comparable.

Results assessed via both polysomnography (PSG — objective sleep laboratory measurement of sleep architecture including sleep stages, onset latency, and wake events) and validated questionnaire tools (Pittsburgh Sleep Quality Index, PSQI):

Statistically significant improvements in sleep onset latency (time to fall asleep)
Increased total sleep time
Improved sleep efficiency (proportion of time in bed actually spent asleep)
Better scores on subjective sleep quality measures
Objective polysomnography data confirmed self-reported improvements — a methodologically important distinction, as sleep studies relying solely on questionnaires are vulnerable to placebo-related reporting bias

GABA-Mimetic Activity and Sleep Onset

The GABA-A receptor partial agonist activity described in the mechanism section is relevant here. GABA is the primary inhibitory neurotransmitter in the central nervous system; GABAergic activity reduces neural excitability and promotes the transition to sleep. Standard sleep medications including benzodiazepines and Z-drugs (zopiclone, zolpidem) work through full GABA-A receptor agonism — at much higher receptor affinity and with well-documented dependence risk.

Ashwagandha's partial GABA-mimetic activity appears to facilitate sleep onset without the dependency profile associated with pharmaceutical sleep aids. The compound triethylene glycol (TEG), found primarily in ashwagandha leaves but present in small quantities in root extracts, has also been implicated in the sleep-promoting effect in animal models.

Practical Context for Australians

Insomnia affects approximately one in four Australians at some point, with chronic insomnia (symptoms lasting more than three months) estimated to affect around 10% of the population. For those seeking non-pharmaceutical support for sleep quality — particularly where the concern is sleep initiation and next-day cognitive performance rather than psychiatric comorbidity — the ashwagandha evidence base is clinically meaningful and growing. A commonly used combination is ashwagandha with magnesium glycinate taken in the evening: ashwagandha addresses the HPA axis and cortisol side of sleep disruption, while magnesium glycinate supports GABA receptor sensitivity and NMDA receptor modulation — complementary mechanisms that address both the stress-driven and neurochemical drivers of poor sleep onset.

Testosterone and Male Health

Ashwagandha benefits for testosterone are supported by randomised trials, though the magnitude of effect and the populations most likely to respond deserve careful characterisation.

Testosterone Increase in Training Studies

The most cited sports nutrition trial (Wankhede et al., Journal of the International Society of Sports Nutrition, 2015) randomised 57 healthy males undergoing resistance training to 300 mg KSM-66 twice daily (600 mg total) or placebo for 8 weeks. The KSM-66 group showed:

~17% increase in testosterone (mean increase of approximately 96 ng/dL versus 18 ng/dL in placebo)
Significantly greater gains in bench press and leg press strength
Lower creatine kinase levels post-exercise (a marker of muscle damage)

The testosterone increase of ~17% is clinically meaningful within a physiological range — it represents optimisation rather than pharmacological elevation. For context, this is not the testosterone increase associated with exogenous androgen administration; it is an enhancement that could plausibly shift a male with borderline-low normal testosterone toward a more optimal range.

Sperm Quality and Male Fertility

A 2010 study by Ambiye and colleagues, published in Evidence-Based Complementary and Alternative Medicine, enrolled 46 men with low sperm count. Those receiving 675 mg ashwagandha root extract daily for 90 days demonstrated:

14% increase in serum testosterone from baseline
167% improvement in sperm count
57% improvement in sperm motility
53% increase in sperm volume relative to placebo

The proposed mechanism involves LH (luteinising hormone) stimulation and reduced oxidative stress in testicular tissue. Cortisol and testosterone are metabolically antagonistic — elevated cortisol chronically suppresses LH and, consequently, Leydig cell testosterone production. By reducing HPA axis overactivation, ashwagandha may create a more favourable hormonal environment for endogenous testosterone synthesis.

It is worth noting that the most robust sperm quality data comes from men with subfertility or documented low baseline values. Benefits in eugonadal men with normal testosterone may be more modest.

Thyroid Function and Hashimoto's

The thyroid-ashwagandha relationship is among the most clinically significant — and most frequently misrepresented — of all ashwagandha benefits. It requires careful, balanced treatment.

TSH Normalisation in Subclinical Hypothyroidism

A randomised, double-blind, placebo-controlled pilot study published in the Journal of Alternative and Complementary Medicine (2018) enrolled 50 adults with subclinical hypothyroidism — defined as elevated TSH with normal free T3 and T4, a common finding on thyroid panels that is frequently asymptomatic but associated with fatigue, cold intolerance, and mild cognitive slowing in some individuals. Participants receiving 600 mg ashwagandha root extract daily for 8 weeks showed:

Statistically significant reductions in TSH (indicating improved thyroid stimulation)
Significant increases in free T4 and free T3
No adverse effects reported

This finding is mechanistically plausible: the HPA and HPT (hypothalamic-pituitary-thyroid) axes are tightly coupled. Chronic stress and elevated cortisol are well-documented suppressors of thyroid function via both central (hypothalamic TRH release) and peripheral (T4-to-T3 conversion) mechanisms. Ashwagandha's HPA-normalising effects may secondarily improve thyroid axis function in those with stress-related thyroid suppression.

Subclinical hypothyroidism is particularly prevalent in Australian women over 40, making this a potentially relevant finding for a meaningful segment of the population — though the pilot study scale requires replication before clinical recommendations can be made confidently. Anyone monitoring thyroid markers alongside ashwagandha use will find it useful to understand what TSH, Free T3, and Free T4 results actually mean — our guide to reading a blood panel for hormone optimisation covers these markers and how to track trends over time.

Hashimoto's Thyroiditis: Proceed with Caution

For those with Hashimoto's thyroiditis (autoimmune hypothyroidism), the picture is more complex. Because withanolides appear to have immunostimulatory effects, there is a theoretical concern that augmenting immune activity in an autoimmune condition could worsen antibody-mediated thyroid destruction. Human evidence specifically in Hashimoto's is limited and mixed.

Some practitioners use ashwagandha cautiously in Hashimoto's patients who are hypothyroid (and on stable thyroid medication), monitoring TSH and antibody levels. Others avoid it entirely due to the immune-stimulation concern. The prudent position: ashwagandha for Hashimoto's should only be used under close practitioner supervision with regular thyroid function monitoring.

Critical Caution: Hyperthyroidism and Graves' Disease

Precisely because ashwagandha appears capable of upregulating thyroid hormone levels, it carries genuine risk for individuals with hyperthyroidism (overactive thyroid) or Graves' disease. Multiple case reports in peer-reviewed literature have documented ashwagandha triggering or significantly worsening thyrotoxicosis in susceptible individuals. This is not a theoretical risk — the mechanism is plausible and the adverse event reports are documented.

Ashwagandha is contraindicated in hyperthyroidism and Graves' disease. This is not a supplement to self-prescribe with any known overactive thyroid condition.

Athletic Performance: VO2 Max, Muscle Recovery

Beyond testosterone support, ashwagandha has been specifically studied for physical performance outcomes in competitive and recreational athletes.

KSM-66 8-Week Elite Athlete RCT

A randomised, double-blind, placebo-controlled study published in the Journal of Ayurveda and Integrative Medicine (2012) examined 500 mg ashwagandha root extract twice daily in elite Indian cyclists for 8 weeks. Outcomes measured included:

VO2 max — the gold standard measure of aerobic capacity, representing the maximum rate of oxygen consumption during incremental exercise
Time to exhaustion on a standardised cycling test
Time to fatigue at a set workload

Results: the ashwagandha group demonstrated statistically significant improvements in VO2 max, time to exhaustion, and time to fatigue compared to placebo. These are performance-relevant outcomes, not merely biomarker changes.

Muscle Strength and Grip Strength Data

The 2015 Journal of the International Society of Sports Nutrition trial referenced in the testosterone section also measured strength outcomes directly. Men receiving 300 mg KSM-66 twice daily during an 8-week resistance training programme experienced:

Significantly greater improvements in bench press strength (46 kg increase vs 26.4 kg in placebo)
Significantly greater improvements in leg extension strength
Substantially lower exercise-induced creatine kinase elevations, indicating reduced muscle damage
Faster self-reported recovery between sessions

Grip strength was assessed in a subsequent trial in older adults using ashwagandha supplementation alongside resistance training; improvements were observed in this population as well, suggesting the performance benefits extend beyond young male athlete populations.

Proposed Mechanisms

No single mechanism accounts for all the performance findings. The most likely contributors are:

Reduced cortisol-mediated catabolism — cortisol drives muscle protein breakdown; normalising cortisol reduces this catabolic signal
Testosterone support — as documented above, even modest testosterone optimisation has compound effects on muscle protein synthesis and strength adaptation
Reduced oxidative stress — withanolides have documented antioxidant activity; lower post-exercise oxidative burden accelerates recovery
Possible mitochondrial efficiency improvements — some preclinical data suggests withanolide D may support mitochondrial biogenesis, though human data on this mechanism is limited

The convergence of these mechanisms makes ashwagandha one of the more evidence-supported natural performance compounds available to Australian athletes, particularly given its clean safety profile relative to more aggressive ergogenic approaches. For athletes also looking to support connective tissue integrity alongside these hormonal and cortisol-related performance benefits, the evidence behind collagen peptides for muscle recovery and joint health covers a complementary nutritional approach targeting the structural side of the training equation.

Dosage, Forms, and Australian Products

Dosage is where supplement marketing frequently diverges from clinical evidence. The ranges used in published human trials are reasonably consistent and provide a practical reference.

Clinically Studied Doses

For stress and cortisol reduction: The most-cited protocol — Chandrasekhar et al. 2012 — used 300 mg KSM-66 twice daily (600 mg total). The 2019 Medicine (Baltimore) trial demonstrated effects at 240 mg daily of a concentrated extract, suggesting dose flexibility when standardisation is high.

For sleep quality: The Shoden trial used 120 mg of a 35% withanolide glycoside extract — a lower mass dose but high absolute withanolide content. KSM-66 sleep studies typically use 300 mg twice daily. Many practitioners recommend an evening dose of 300–600 mg KSM-66 for sleep-focused use.

For testosterone and male health: Most trials use 600 mg KSM-66 daily (300 mg twice daily), with the Ambiye fertility study using 675 mg daily.

For athletic performance: Studies range from 500 mg twice daily (1,000 mg total) for aerobic performance to 300 mg twice daily (600 mg total) for the resistance training/testosterone protocol.

Sensoril dosage: Sensoril trials typically use 250 mg daily — effective at a lower mass dose due to the higher withanolide percentage (10%+).

Timing Considerations

KSM-66 is generally well tolerated at any time of day. For stress and cortisol applications, splitting the dose (morning and evening) mirrors the cortisol diurnal rhythm and the trial protocols. For sleep-focused use, a single evening dose of 300–600 mg 30–60 minutes before bed is the most common practitioner-recommended approach.

Ashwagandha can be taken with or without food; some individuals find it easier on the stomach with a small meal.

Cycling

There is no pharmacological evidence requiring cycling, and most trials run continuously for 8–12 weeks without evidence of tolerance development. However, the general adaptogen convention — 8 weeks on, 2–4 weeks off — is a reasonable precautionary approach, particularly when using ashwagandha for extended periods.

Australian Products

Products available through Australian pharmacies, health food stores, and online retailers include:

Swisse Ashwagandha — widely available through Chemist Warehouse, Priceline, and major supermarkets; typically uses KSM-66 at doses around 300–600 mg; check the label for the specific extract and dose per serving
Blackmores Ashwagandha — available at mainstream pharmacies; uses standardised root extract; verify the specific extract name on current formulations
Herbs of Gold Ashwagandha — available at health food stores and independent pharmacies; often uses KSM-66 with transparent standardisation; a generally quality-conscious brand for the Australian market
Practitioner-grade products — brands such as Bioceuticals, Metagenics, and Orthoplex distribute KSM-66 and Sensoril formulations through integrative and naturopathic practitioners, often with clearer dosage specifications

When evaluating any Australian ashwagandha product, look for:

AUST L number — confirms TGA listing and quality/safety review
Extract name stated (KSM-66, Sensoril, or other identified extract)
Withanolide percentage declared (5% minimum for KSM-66 root-only products)
Dose per serving in milligrams, not just "equivalent to" dried herb quantities

Safety, Contraindications, Drug Interactions

Ashwagandha has a well-established safety profile in healthy adults at standard doses, but specific contraindications and interactions are clinically significant and should not be minimised.

Contraindications

Pregnancy: Ashwagandha has documented uterine-stimulant properties in preclinical models, and its traditional Ayurvedic use includes references to abortifacient activity at high doses. Avoid entirely during pregnancy — there is no adequate evidence of safety in this context.

Hyperthyroidism and Graves' disease: Contraindicated as detailed in the thyroid section. Case reports of thyrotoxicosis are documented in peer-reviewed literature.

Active autoimmune disease: The immunostimulatory properties of withanolides may theoretically worsen autoimmune conditions where immune activity is already pathologically elevated — including lupus, rheumatoid arthritis, and multiple sclerosis. Human evidence is limited, but caution is appropriate; use only under close practitioner supervision.

Nightshade allergy or sensitivity: As a Solanaceae member, ashwagandha may provoke reactions in those with documented nightshade sensitivity. Patch reactions and gastrointestinal sensitivity have been reported.

Drug Interactions

Thyroid medications (thyroxine, liothyronine): Given ashwagandha's documented ability to raise T3 and T4 levels in subclinical hypothyroidism, concurrent use with thyroid hormone replacement may result in excessive thyroid hormone levels. Anyone taking thyroid medication should not add ashwagandha without discussing it with their prescribing doctor and planning appropriate monitoring.

Sedatives and CNS depressants: The GABA-mimetic activity of withanolides creates a potential additive or synergistic effect with benzodiazepines, Z-drugs (zopiclone, zolpidem), and other CNS depressants. Combined use should only occur under medical supervision.

Immunosuppressants: The immunostimulatory properties of ashwagandha may antagonise the effect of immunosuppressant medications used in transplant recipients and autoimmune disease management (including tacrolimus, cyclosporine, and corticosteroids). This is a meaningful clinical interaction.

Blood pressure medications: Some evidence suggests ashwagandha may have mild blood pressure-lowering effects, which could potentiate antihypertensive medications.

Adverse Effects in Trials

Reported adverse effects in clinical trials are generally mild and dose-related:

Gastrointestinal discomfort and loose stools (most common; typically self-resolving and reduced by taking with food)
Drowsiness at higher doses in sensitive individuals

Serious adverse events are rare in trial data. Rare case reports of liver injury have been published; the causal relationship is debated, but it warrants awareness. Using established branded extracts (KSM-66, Sensoril) from products with AUST L numbers rather than uncharacterised powders is a meaningful risk-reduction strategy.

FAQ

How long does ashwagandha take to work?

Most clinical trials show measurable effects on stress, cortisol, and anxiety at 4–6 weeks, with optimal outcomes at 8–12 weeks of consistent use. Some individuals report a mild calming effect within the first one to two weeks — likely reflecting the more immediate GABA-mimetic activity. The deeper hormonal and HPA axis changes that produce the sustained cortisol-reduction and sleep quality improvements take considerably longer to establish. Patience is genuinely required; assessing ashwagandha on a one-week trial is not clinically meaningful.

Can I take ashwagandha with thyroid medication?

This is one of the most important safety questions for Australian users, given the high prevalence of thyroid conditions particularly in women. Do not combine ashwagandha with thyroid medication without discussing it with your prescribing doctor first. Ashwagandha has documented capacity to raise T3 and T4 levels; adding it to an existing thyroid hormone replacement dose could push levels too high. If your doctor agrees to trial it, thyroid function testing should be planned at regular intervals.

Morning or night — when is the best time to take it?

The answer depends on your primary goal. For stress and cortisol management, splitting the dose (morning and evening) mirrors published trial protocols and aligns with the cortisol diurnal curve. For sleep-focused use, a single evening dose 30–60 minutes before bed is the most evidence-aligned approach. For athletic performance, taking it around training sessions is a reasonable approach, though the evidence supports consistent daily use more than acute timing effects.

Which form is best — KSM-66, Sensoril, or powder?

For most applications, KSM-66 is the better-evidenced starting point — it has the largest and most diverse human RCT portfolio, covers stress, cortisol, testosterone, and athletic performance applications, and is available at appropriate doses in multiple Australian products. Sensoril is a credible alternative, particularly for sleep-focused use or where a lower dose is preferred. Non-standardised ashwagandha powder has thousands of years of traditional use but makes it difficult to reliably achieve the doses studied in clinical trials — the withanolide content of bulk powders varies significantly by batch and source.

Does ashwagandha work for women?

Yes — though the evidence base is more limited than for men. The cortisol reduction, stress, anxiety, and sleep benefits have been demonstrated in mixed-sex populations or explicitly in women. The thyroid normalisation data from the subclinical hypothyroidism trial is particularly relevant to women (hypothyroidism is substantially more prevalent in women). There is emerging but limited research on ashwagandha for perimenopausal symptoms, including hot flushes and sleep disruption, with some preliminary positive signals. Women's hormonal health outcomes specifically — menstrual cycle effects, progesterone, oestrogen interactions — remain substantially understudied and warrant caution in the absence of clearer evidence. As always, any woman who is pregnant or breastfeeding should avoid ashwagandha entirely.